Shepherd B B - OmicsDI

Show results for

Unknown (842)
Transcriptomics (48)
Proteomics (36)
Genomics (24)
Metabolomics (2)
Genomic (1)

Organisms

Homo sapiens (66)
Mus musculus (10)
Helicobacter pylori (5)
Solanum tuberosum (3)
Arabidopsis thaliana (2)
Canis lupus familiaris (2)
Rattus norvegicus (2)
Escherichia coli (2)
Plasmodium falciparum 3D7 (2)
Capsella grandiflora (1)
Arabidopsis lyrata (1)
Oncorhynchus mykiss (1)
Triticum aestivum (1)
Sus scrofa (1)
Danio rerio (1)
Drosophila melanogaster (1)
Bacteria (1)
Candida albicans (1)
Influenza A virus (A/California/04/2009(H1N1)) (1)
Microcaldota (1)
environmental samples (1)

Organisms

Homo sapiens (2)
Drosophila melanogaster (1)

Repository

biostudies-arrayexpress (48)
pride (33)
EGA (20)
MassIVE (3)
ENA (3)
MetaboLights (2)
dbGaP (1)
geo (1)

Tissue

Blood (2)
Blood plasma (2)
Breast (2)
Cell culture (2)
Epithelial cell (2)
Liver (2)
Lung (2)
Bone marrow (1)
Brain (1)
Bronchoalveolar lavage (1)
Esophagus (1)
Fibroblast (1)
Gastric juice (1)
Heart (1)
JURKAT cell (1)
Muscle (1)
Myeloid cell (1)
Photosynthetic cell (1)
Stomach (1)
Urinary bladder (1)

Disease

Breast cancer (3)
None (1)
Disease free (1)
Hepatitis (1)
Herpes simplex (1)
Idiopathic pulmonary fibrosis (1)
Influenza (1)
Juvenile myelomonocytic leukemia (1)
Lung adenocarcinoma (1)
Lung squamous cell carcinoma (1)
Malignant neoplasm of ovary (1)
Non-small cell lung carcinoma (1)
Plasmodium falciparum malaria (1)
Urinary bladder cancer (1)

Technology Type

Mass Spectrometry (33)
Bottom-up proteomics (12)
Shotgun proteomics (10)
Data-dependent acquisition (9)
Affinity purification coupled with mass spectrometry proteomics (3)
SWATH MS (3)
Mass spectrometry (2)
Data-independent acquisition (2)
Gel-based experiment (2)
Glycoproteomics (2)
Top-down proteomics (2)
Illumina HiSeq 2500 (1)
Affinity proteomics (1)
Immunopeptidomics (1)
Olink affinity proteomics (1)
SRM/MRM (1)

Instrument Platform

NextSeq 2000 (2)
TripleTOF 5600 (2)
- (1)
Illumina HiSeq 2500 (1)
Illumina HiSeq 2000 (1)
Orbitrap Fusion (1)
Gas Chromatography MS - positive (1)
Q Exactive (1)

Publication Date

2010 (10)
2025 (10)
2026 (9)
2011 (9)
2024 (8)
2013 (5)
2008 (5)
2022 (5)
2023 (4)
2015 (3)
2006 (3)
2019 (2)
2017 (2)
2016 (2)
2014 (2)
2009 (2)
2005 (2)
2021 (2)
2020 (2)

CHEBI ID

CHEBI:15746 (2)
CHEBI:16010 (2)
CHEBI:16113 (2)
CHEBI:16199 (2)
CHEBI:16411 (2)
CHEBI:16530 (2)
CHEBI:16958 (2)
CHEBI:17148 (2)
CHEBI:17268 (2)
CHEBI:17620 (2)
CHEBI:17822 (2)
CHEBI:17924 (2)
CHEBI:17964 (2)
CHEBI:17992 (2)
CHEBI:18012 (2)
CHEBI:18186 (2)
CHEBI:18237 (2)
CHEBI:18257 (2)
CHEBI:26078 (2)
CHEBI:27389 (2)
CHEBI:28037 (2)
CHEBI:28044 (2)
CHEBI:28790 (2)
CHEBI:30769 (2)
CHEBI:30915 (2)
CHEBI:33508 (2)
CHEBI:6650 (2)
CHEBI:76341 (2)
CHEBI:7916 (2)
CHEBI:10072 (1)

Metabolite Name

3-amino-2-piperidone (2)
5-oxoproline (2)
Beta-alanine (2)
Glycerol 3-phosphate (2)
Myo-inositol (2)
Ornithine (2)
Phenylalanine (2)
Putrescine (2)
Serine (2)
Serotonin (2)
Spermine (2)
Sucrose (2)
Tyrosine (2)
(R)-3-hydroxybutyrylcarnitine (1)
1-(1-enyl-palmitoyl)-2-arachidonoyl-GPC (P-16:0/20:4)* (1)
1-(1-enyl-palmitoyl)-2-arachidonoyl-GPE (P-16:0/20:4)* (1)
1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (P-16:0/18:2)* (1)
1-(1-enyl-palmitoyl)-2-linoleoyl-GPE (P-16:0/18:2)* (1)
1-(1-enyl-palmitoyl)-2-palmitoleoyl-GPC (P-16:0/16:1)* (1)
1-(1-enyl-palmitoyl)-2-palmitoyl-GPC (P-16:0/16:0)* (1)
1-(1-enyl-palmitoyl)-GPE (P-16:0)* (1)
1-(1-enyl-stearoyl)-2-linoleoyl-GPE (P-18:0/18:2)* (1)
1-(1-enyl-stearoyl)-GPE (P-18:0)* (1)
1-arachidonoyl-GPA (20:4) (1)
1-arachidonoyl-GPI (20:4)* (1)
1-lignoceroyl-GPC (24:0) (1)
1-linolenoyl-GPC (18:3)* (1)
1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6)* (1)
1-linoleoyl-GPA (18:2)* (1)
1-linoleoyl-GPC (18:2) (1)

First Public Date

2023 (2)
2022 (1)

Study type

Transcription profiling by array (29)
RNA-seq of coding RNA (10)
Unknown experiment type (2)
Genotyping by array (2)
Comparative genomic hybridization by array (2)
Methylation profiling by array (2)
DNA-seq (1)

Release Date

2021 (93)
2022 (92)
2020 (82)
2023 (72)
2024 (67)
2025 (65)
2019 (60)
2018 (50)
2016 (40)
2017 (38)
2015 (35)
2014 (33)
2011 (32)
2010 (29)
2012 (27)
2013 (24)
2026 (16)
2009 (8)
2008 (8)
2006 (6)
2007 (5)
2005 (2)
2004 (2)
2002 (2)
2000 (1)
1999 (1)

Lab affiliation

University of Oxford University of Dundee (3)
BCI Mass Spectrometry Facility 10,2 &1.03 First Floor John Vane Science Centre Bars Cancer Institute, Queen Mary Charterhouse square London EC1M 6BQ (1)
Centre for Proteome Research, University of Liverpool (1)
Department of Biochemistry & Pharmacology, Bio21 Molecular Science and Biotechnology Institute The University of Melbourne, Victoria, 3010 Australia (1)
Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton 3800, Victoria, Australia (1)
Department of Biochemistry, Schulich School of Medicine and Dentistry, Western University, London, ON, N6A 5C1, Canada (1)
Department of Molecular Biology, Princeton University (1)
Department of Pathology, University of Michigan Gilbert S. Omenn Department of Computational Medicine and Bioinformatics, University of Michigan (1)
Department of Thoracic Surgery, First Affiliated Hospital of Kunming Medical University, Kunming 650000, Yunnan, China. (1)
Functional Proteomics, ICR (1)
General Manager of PROMEC Department of Clinical and Molecular Medicine lars.hagen@ntnu.no +4773598508 +4772573342 Laboratoriesenteret, 231.04.008, Øya, Erling Skjalgssons gate 1 Norway (1)
Head, Cancer Data Science (ProCan), Children's Medical Research Institute, The University of Sydney, Westmead, NSW, Australia (1)
Imperial College London, Department of Life Sciences, UK (1)
Institute of Chemical Technologies and Analytics, TU Wien, Getreidemarkt 9, 1060 Vienna, Austria; Research and Diagnostic Institute of Pathology, Medical University of Graz, Stiftingtalstraße 6, 8036, Graz, Austria (1)
Institute of Structural and Molecular Biology, Division of Biosciences, University College London, London, United Kingdom (1)
Institutt for BIoingeniørfag (IBF), and CEMIR NTNU, Kunnskapssenteret, Øya, 7030, Norway (1)
International Centre for Cancer Vaccine Science, University of Gdansk, Kladki 24, Gdansk, Poland (1)
Liverpool John Moores University (1)
Marine Chemistry Geochemistry, Woods Hole Oceanographic Institution, US (1)
Mass Spectrometry Facility Barts Cancer Institute, Queen Mary,University of LondonRoom 1.02-1.03, 1st Floor, John Vane Science Centre Charterhouse Square London EC1M 6BQ (1)
Max Planck Institute of Biophysics (1)
Mode of Action Group, Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee (1)
Murdoch Children's Research Institute Parkville, Victoria, 3052 Australia (1)
Principal Investigator, University of Dundee (1)
ProCan, Children's Medical Research Institute, 214 Hawkesbiry Rd, Westmead, NSW 2145 Australia (1)
Research Center of IPO Porto (CI-IPOP)/CI-IPOP@RISE (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC) (1)
Technische Universität München, School of Natural Sciences, Department of Bioscience and Center for Functional Protein Assemblies, Ernst-Otto-Fischer-Straße 8, 85747 Garching, Germany (1)
The Hospital for Sick Children (1)
The Rosalind Franklin Institute, Oxfordshire, United Kingdom Department of Pharmacology, University of Oxford (1)
Universitaet fuer Bodenkultur Department fuer Chemie Muthgasse 18 A-1190, Wien, Austria (1)

Tags

xref:PubMed:38225354 (1)
xref:PubMed:36542473 (1)
xref:PubMed:37018654 (1)

Previous page
1 / 96
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 96
Next page

Sort by:

Relevance

Page size

Influenza B-derived peptide presentation by HLA-B*07:02, -B*08:01 and -B*35:01

Analysis of peptide presentation by Human Leukocyte Antigen (HLA) class I of influenza B infected C1R cells expressing HLA-B*07:02, -B*08:01 or -B*35:01.

ORGANISM(S): Homo sapiens (Human)

2024-03-04 | PXD045000 | Pride

NCIC CTG MA.22 phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer on 2-weekly or 3-weekly schedules

This phase I/II neoadjuvant trial determined maximally-tolerated doses (MTD), dose-limiting toxicities (DLT), response-to-therapy, and explored the role of new response biomarkers. The combination regimens were delivered with acceptable toxicity, good clinical response, inducing changes in tumor RNA...

ORGANISM(S): Homo sapiens

2015-11-11 | E-GEOD-66999 | biostudies-arrayexpress

Autosomal recessive hyposegmentation of granulocytes in Australian Shepherd Dogs indicates a role for LMBR1L in myeloid leukocytes.

Not available

S-EPMC10321630 | biostudies-literature

A hypomyelinating leukodystrophy in German Shepherd dogs.

Not available

S-EPMC8163122 | biostudies-literature

Genome-Wide Analyses Suggest Mechanisms Involving Early B-Cell Development in Canine IgA Deficiency.

Not available

S-EPMC4520476 | biostudies-literature

Synthesis and Biological Evaluation of Vioprolide B and its Dehydrobutyrine-Glycine Analogue

Herein, we describe the total synthesis of the depispeptide vioprolide B and of an analogue, in which the (E)-dehydrobutyrine amino acid was replaced by glycine. The compounds were studied in biological assays which revealed cytotoxicity solely for vioprolide B presumably by covalent binding to cyst...

ORGANISM(S): Homo sapiens (Human)

2024-07-17 | PXD053104 | Pride

Proteomics Natural product Target id

Structure reassignment of laurefurenynes A and B by computation and total synthesis.

Not available

S-EPMC4280896 | biostudies-literature

B cells mediate lung ischemia/reperfusion injury by recruiting classical monocytes via synergistic B cell receptor/TLR4 signaling.

Not available

S-EPMC10940088 | biostudies-literature

Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29.

Not available

S-EPMC4681581 | biostudies-literature